Extrapulmonary Neuroendocrine Carcinoma

Extrapulmonary Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 104
Recruiting: 46
Ph III recruiting: 1
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (50)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00363051	Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy	completed	Phase 2	160	Novartis PharmaceuticalsINDUSTRY	11	May 10, 2013	clinicaltrials
NCT00068783	S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer	completed	Phase 2	40	National Cancer Institute (NCI)NIH	1	Feb 28, 2013	clinicaltrials